These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 30256723)

  • 21. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke.
    Milonas D; Tziomalos K
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):134-138. PubMed ID: 29412119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.
    Avranas K; Imprialos K; Stavropoulos K; Lales G; Manafis A; Skalkou A; Kihm L
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):94-103. PubMed ID: 29412124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure.
    Riggs K; Ali H; Taegtmeyer H; Gutierrez AD
    Metab Syndr Relat Disord; 2015 Sep; 13(7):292-7. PubMed ID: 26125313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
    Inzucchi SE; Zinman B; Wanner C; Ferrari R; Fitchett D; Hantel S; Espadero RM; Woerle HJ; Broedl UC; Johansen OE
    Diab Vasc Dis Res; 2015 Mar; 12(2):90-100. PubMed ID: 25589482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives.
    Garla VV; Butler J; Lien LF
    Curr Cardiol Rep; 2021 May; 23(6):59. PubMed ID: 33961133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
    Imprialos KP; Sarafidis PA; Karagiannis AI
    J Hypertens; 2015 Nov; 33(11):2185-97. PubMed ID: 26372321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
    Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors.
    Cersosimo E; Miles JM
    Curr Diabetes Rev; 2019; 15(4):314-327. PubMed ID: 30101716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
    Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jørgensen ME; Wittbrodt ET; Thuresson M; Bodegård J; Hammar N; Fenici P;
    Diabetes Obes Metab; 2018 Aug; 20(8):1983-1987. PubMed ID: 29569378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: Overview of the Efficacy and Safety of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus.
    Miller EM
    J Fam Pract; 2017 Feb; 66(2 Suppl):S5-S12. PubMed ID: 28222460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
    Papademetriou V; Geladari E
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
    Rajasekeran H; Cherney DZ; Lovshin JA
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 40. The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
    Loutradis C; Papadopoulou E; Angeloudi E; Karagiannis A; Sarafidis P
    Curr Med Chem; 2020; 27(39):6682-6702. PubMed ID: 31663470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.